|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||0.00 - 0.00|
|Beta (5Y monthly)||0.67|
|PE ratio (TTM)||34.02|
|Earnings date||17 Oct 2023 - 23 Oct 2023|
|Forward dividend & yield||2.04 (2.02%)|
|Ex-dividend date||13 Jul 2023|
|1y target est||N/A|
Abbott (ABT) closed at $98.93 in the latest trading session, marking a -1.35% move from the prior day.
Abbott (ABT) is set to commercialize several biosimilar molecules in key emerging markets via an expanded collaboration with mAbxience.
Abbott (ABT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.